MYRIAD GENETICS ($MYGN) is expected to release its quarterly earnings data on Thursday, January 15th after market close, per Finnhub. Analysts are expecting revenue of $210,962,132 and earnings of -$0.02 per share.
You can see Quiver Quantitative's $MYGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MYRIAD GENETICS Revenue
MYRIAD GENETICS had revenues of $205.7M in Q3 2025. This is a decrease of -3.56% from the same period in the prior year.
You can track MYGN financials on Quiver Quantitative's MYGN stock page.
MYRIAD GENETICS Hedge Fund Activity
We have seen 116 institutional investors add shares of MYRIAD GENETICS stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,492,405 shares (+157.0%) to their portfolio in Q3 2025, for an estimated $10,790,088
- VANGUARD GROUP INC removed 1,374,978 shares (-14.9%) from their portfolio in Q3 2025, for an estimated $9,941,090
- KENT LAKE PR LLC removed 1,250,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,037,500
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,163,400 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $8,411,382
- CITADEL ADVISORS LLC removed 1,138,871 shares (-66.6%) from their portfolio in Q3 2025, for an estimated $8,234,037
- MORGAN STANLEY removed 937,155 shares (-20.6%) from their portfolio in Q3 2025, for an estimated $6,775,630
- ALGERT GLOBAL LLC added 913,065 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,601,459
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MYRIAD GENETICS Government Contracts
We have seen $14,994 of award payments to $MYGN over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
MYRIAD GENETICS Analyst Ratings
Wall Street analysts have issued reports on $MYGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/11/2025
To track analyst ratings and price targets for MYRIAD GENETICS, check out Quiver Quantitative's $MYGN forecast page.
MYRIAD GENETICS Price Targets
Multiple analysts have issued price targets for $MYGN recently. We have seen 4 analysts offer price targets for $MYGN in the last 6 months, with a median target of $8.25.
Here are some recent targets:
- Dave Weiner from Piper Sandler set a target price of $8.5 on 11/11/2025
- Brandon Couillard from Wells Fargo set a target price of $6.5 on 11/05/2025
- Lu Li from UBS set a target price of $8.0 on 11/04/2025
- Dan Brennan from TD Cowen set a target price of $9.0 on 11/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
